Published on 18/02/2010
A new drug developed for kidney transplant patients can reduce the risk of organ rejection, with fewer side effects and improved preservation of renal function than current treatments.
New research published in the American Journal of Transplantation indicates that belatacept is effective as a post-transplant alternative to drugs most commonly used to suppress the immune system.
According to the study, the tested treatment results in superior kidney function in transplant patients after 12 months.
Commenting on the findings, lead researcher Dr Flavio Vincenti said: "Our findings show that this will be a novel and more specific way of suppressing the immune system with less toxicity.
"It will target the specific responses that cause rejection of transplanted organs with less damage to other systems of the body."
The UK National Kidney Federation reports that on average, patients on the waiting list for two years have a 50 per cent chance of being offered an organ.
© ActiveQuote Health Ltd. 2010
Categories: Medical
Related Health Insurance News Articles
08/02/2012Hospital superbug C. difficle source is unclear, say scientistsScientists cannot explain how 75 per cent of people catch the superbug C. difficile, after a study showed that only a quarter of infections in one hospital system were traced to contact with a suffering...
09/02/2012Coronary heart disease gene is passed from father to sonUp to one in five men is carrying a gene from their father that increases their risk of coronary heart disease by 50 per cent. A study has found that men can inherit a form of heart disease from their father...
09/02/2012Fasting paired with chemotherapy significantly slows the growth of cancer cellsAn interesting new study indicates that starvation paired with chemotherapy can significantly reduce the growth of cancer cells, matching or improving the effects of chemotherapy alone. Scientists at the...
10/02/2012Scientists reverse effects of Alzheimer's in mice using skin cancer drug bexaroteneScientists have reversed the effects of Alzheimer’s disease in mice using an already licensed skin cancer drug. Destructive plaques commonly found in the brains of Alzheimer’s patients were broken...
10/02/2012Chemotherapy during pregnancy does not harm the unborn childChemotherapy during pregnancy does not necessarily harm the unborn child, according to a ground-breaking new report. The study, published in the Lancet Oncology journal, shows that children born to women...